Big Buttons

• PFMs can get 2.5% credit card processing

  A new benefit for APC’s Pharmacy/Facility Members: They may be able to cut their credit card processing fees to just 2.5% – 2.8%. read more →

• Phoenix compounders, rise!

  The latest of APC’s new regional meetings — CompoundED UpDATE — is coming to the Phoenix area December 5. read more →

• APC election results: directors and bylaws

  See the results of APC's elections, including four new directors and several changes to our bylaws. read more →

• Bring us your expertise — join an APC standing committee

  We’re seeking knowledgeable members for seven 2025 APC standing committees. Is that you? read more →

• You don’t have to miss our GLP-1 briefing

  Our briefing, “What's Up with GLP-1 Compounding (And What's Next)?” is now available on demand. read more →

• PCAC votes against four nominated bulk drug substances

  FDA’s Pharmacy Compounding Advisory Committee voted at a meeting Tuesday against adding four substances to the 503A bulks list. read more →

• Did someone mention glass houses?

  Oopsie! The FDA has cited Novo Nordisk for “quality lapses” at one of the company’s two Ozempic manufacturing plants. read more →

• GLP-1s: Keep your patients informed

  The P3 October newsletter is perfect for explaining GLP-1s to your patients. read more →

More News

The FDA has cited Novo Nordisk for “quality lapses” at one of the company’s two Ozempic manufacturing plants. This facility, in Denmark, is the second Novo plant dinged for potential contamination issues — the other is in North Carolina. The Denmark issue is bad enough that the company doesn’t expect it to be resolved this year.